ABSTRAK
Latar belakang : Pasien HIV berisiko 20-37 kali lipat terinfeksi TB, dan TBmerupakan penyebab kematian tertinggi pada HIV. Resistensi OAT menjadimasalah utama dalam pengobatan TB terutama pada pasien HIV, hal ini berujungpada peningkatan mortalitas dan biaya. Rifampisin merupakan OAT utama,dibuktikan dengan kesembuhan yang rendah pada regimen tanpa rifampisin,sehingga perlu diketahui prevalensi resistensi rifampisin dan faktor-faktor yangmempengaruhi pada pasien TB-HIV. Tujuan : Mengetahui prevalensi resistensi rifampisin pada pasien TB-HIV danfaktor-faktor yang mempengaruhi. Metode : Studi potong lintang terhadap 196 pasien TB-HIV yang menjalanipemeriksaan Xpert MTB-RIF di poli pelayanan terpadu HIV RSUPN CiptoMangunkusumo selama tahun 2012-2015. Analisa bivariat untuk mengetahuihubungan faktor-faktor dengan kejadian resistensi rifampisin. Analisa multivariatmenggunakan uji regresi logistik. Hasil dan Pembahasan : Pada 196 pasien yang menjadi subjek penelitian,didapatkan prevalensi resistensi rifampisin sebesar 13,8%. Usia, jenis kelamin,riwayat penggunaan ARV, dan TB ekstra paru tidak berhubungan dengankejadian resistensi rifampisin pada TB-HIV. CD4 < 100 mempengaruhi kejadianresistensi rifampisin (OR 2,57; 95% IK 0,99-6,69), Riwayat pengobatan TBmempengaruhi kejadian resistensi rifampisn (OR 3,98; 95% IK 1,68-9,44). Kesimpulan : Prevalensi resistensi rifampisin TB-HIV di RSUPN CiptoMangunkusumo sebesar 13,8%. Riwayat TB mempengaruhi kejadian resistensi rifampisin pada pasien TB-HIV. ABSTRACT
Background: HIV patients have 20-37 fold risk of getting TB infection and TB isthe leading cause of death among them. Anti tuberculosis drug resistance is amajor problem in the treatment of tuberculosis with rifampicin as one of the maindrug. We need more information about prevalence of rifampicin resistance and itscontributing factors in TB-HIV patients. Aim: To determine the prevalence of rifampicin resistance in TB-HIV patientsand its contributing factors. Method : A cross sectional study of 196 TB-HIV patients who underwent XpertMTB/RIF examination at Cipto Mangunkusumo Hospital during the year 20122105.Correlationbetweenprevalenceofrifampicinresistanceanditscontributingfactorswas done using bivariate analysis. Multivariate analysis was done usinglogistic regression test. Result and Discussion : From 196 patients, we found prevalence of 13,8%rifampicin resistance. CD4 < 100 affects the incidence of rifampicin resistance(OR2.5;95% CI 0.99-6.69). Hiistory of TB treatment affects the incidence ofrifampicin resistance (OR3.98;95%CI 1.68-9.44). Conclusion : Prevalence of rifampicin resistance in TB-HIV patients in CiptoMangunkusumo Hospital is 13.8%. History of TB treatment affects the incidenceof rifampicin resistance in TB-HIV patients. ;Background: HIV patients have 20-37 fold risk of getting TB infection and TB isthe leading cause of death among them. Anti tuberculosis drug resistance is amajor problem in the treatment of tuberculosis with rifampicin as one of the maindrug. We need more information about prevalence of rifampicin resistance and itscontributing factors in TB-HIV patients. Aim: To determine the prevalence of rifampicin resistance in TB-HIV patientsand its contributing factors. Method : A cross sectional study of 196 TB-HIV patients who underwent XpertMTB/RIF examination at Cipto Mangunkusumo Hospital during the year 20122105.Correlationbetweenprevalenceofrifampicinresistanceanditscontributingfactorswas done using bivariate analysis. Multivariate analysis was done usinglogistic regression test. Result and Discussion : From 196 patients, we found prevalence of 13,8%rifampicin resistance. CD4 < 100 affects the incidence of rifampicin resistance(OR2.5;95% CI 0.99-6.69). Hiistory of TB treatment affects the incidence ofrifampicin resistance (OR3.98;95%CI 1.68-9.44). Conclusion : Prevalence of rifampicin resistance in TB-HIV patients in CiptoMangunkusumo Hospital is 13.8%. History of TB treatment affects the incidenceof rifampicin resistance in TB-HIV patients. ;Background: HIV patients have 20-37 fold risk of getting TB infection and TB isthe leading cause of death among them. Anti tuberculosis drug resistance is amajor problem in the treatment of tuberculosis with rifampicin as one of the maindrug. We need more information about prevalence of rifampicin resistance and itscontributing factors in TB-HIV patients. Aim: To determine the prevalence of rifampicin resistance in TB-HIV patientsand its contributing factors. Method : A cross sectional study of 196 TB-HIV patients who underwent XpertMTB/RIF examination at Cipto Mangunkusumo Hospital during the year 20122105.Correlationbetweenprevalenceofrifampicinresistanceanditscontributingfactorswas done using bivariate analysis. Multivariate analysis was done usinglogistic regression test. Result and Discussion : From 196 patients, we found prevalence of 13,8%rifampicin resistance. CD4 < 100 affects the incidence of rifampicin resistance(OR2.5;95% CI 0.99-6.69). Hiistory of TB treatment affects the incidence ofrifampicin resistance (OR3.98;95%CI 1.68-9.44). Conclusion : Prevalence of rifampicin resistance in TB-HIV patients in CiptoMangunkusumo Hospital is 13.8%. History of TB treatment affects the incidenceof rifampicin resistance in TB-HIV patients.